Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD). This study was part of the ChromaDex External Research Program (CERP??), which donated ChromaDex's patented NR ingredient, Niagen®?, the most efficient and high quality NAD+ precursor, for the advancement of this research.

In a pioneering development for PD treatment, this landmark phase I randomized, double-blind clinical study reported in the peer-reviewed journal Nature Communications by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University Hospital and University of Bergen in Norway, demonstrated that supplementing individuals with PD with high-dose (3,000 mg daily) Niagen NR was short-term safe, greatly increased whole blood NAD+ levels, augmented the NAD+ metabolome, and was associated with a significant clinical improvement. These results build upon previous research led by Dr. Tzoulis (Cell Metabolism) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research. With several studies demonstrating the safety and tolerability of 2,000mg of Niagen NR, this marks a milestone as the first-ever clinical study to demonstrate the safety, tolerability, and beneficial effects of high-dose Niagen NR at 3,000 mg per day.

The study was a randomized, double-blind, placebo-controlled, phase I clinical trial in 20 individuals with idiopathic PD fulfilling the criteria set by the Movement Disorders Society (MDS). This promising milestone research demonstrates that high-dose NR at 3,000 u mg per day is safe, well-tolerated, and may improve clinical symptoms for PD. These results set the stage for the long-term NO-PARK Phase II/III clinical study, which will determine if NR can delay disease progression in persons with PD.

Further, Prof. Tzoulis and his team of investigators are conducting the N-DOSE clinical trial to determine the optimal safe dose to assess the efficacy of NR as part of the treatment of PD.